ArticleCancer management and research2013
Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma.
Article in Cancer management and research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 31 citations in OpenAlex.
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.BMC cancer · 2017Trial
- Immunopathogenesis and Therapeutic Implications in Basal Cell Carcinoma: Current Concepts and Future Directions.Medicina (Kaunas, Lithuania) · 2025Review
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database.Frontiers in pharmacology · 2025Article
- Periocular basal cell carcinoma - clinical perspectives.Oncology reviews · 2020Article
- Gli is activated and promotes epithelial-mesenchymal transition in human esophageal adenocarcinoma.Oncotarget · 2018Article
- The best of the best: a review of select oculoplastic case series published in 2015.Digital journal of ophthalmology : DJO · 2017Review
- Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.OncoTargets and therapy · 2017Review
- Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.The oncologist · 2016Review
- Enhanced skin delivery of vismodegib by microneedle treatment.Drug delivery and translational research · 2015Article
- Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.Ophthalmic plastic and reconstructive surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Basal cell carcinoma (BCC) is the most common human malignancy. Recent advances in our understanding of the critical biologic pathways implicated in the development and progression of BCC have led to the development of the first molecular targeted therapy for this disease. The hedgehog pathway is mutated in virtually all patients with BCC and recent trials with vismodegib, an inhibitor of this pathway, have shown significant responses. This review will discuss the importance of the hedgehog pathway in the pathogenesis of BCC and describe in detail the pharmacology of vismodegib in relation to its activity in advanced BCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.